BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma

This publication has 23 references indexed in Scilit:

• 18F-labelled fluorodeoxyglucose–positron emission tomography (FDG–PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma
  European Journal of Cancer, 2013
• Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
  The Lancet, 2012
• Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
  The Lancet, 2012
• Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases
  Acta Neuropathologica, 2011
• Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
  New England Journal of Medicine, 2011
• Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with ^V600EBRAF-mutated melanoma.
  Journal of Clinical Oncology, 2011
• Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody
  Acta Neuropathologica, 2011
• Taking stock of translational research in melanoma at the 2010 Society for Melanoma Research Congress
  Pigment Cell & Melanoma Research, 2010
• Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
  New England Journal of Medicine, 2010
• New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
  European Journal of Cancer, 2009